| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| HAMILTON THORNE Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 343,85 | +1,99 % | Oppenheimer Just Upgraded Intuitive Surgical Stock. Here's Why. | ||
| UNITEDHEALTH | 341,80 | +0,06 % | 32 % im ersten Halbjahr: So investiert der "beste Hedgefondsmanager seiner Generation" jetzt | © Foto: wO-ChatGPT Der außergewöhnlich erfolgreiche Hedgefondsmanager David Tepper zieht Konsequenzen aus seiner China-Wette - und setzt Milliarden neu ein. Seine Rechnung geht meistens auf Enthaltene... ► Artikel lesen | |
| MEDTRONIC | 80,32 | +2,63 % | Piper Sandler reiterates Medtronic stock rating on PFA strength | ||
| TELADOC HEALTH | 5,718 | +1,31 % | Teladoc Health, Inc.: Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors | NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,061 | -4,70 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| SYNLAB | - | - | EQS-News: SYNLAB: Synnovis milestone: 2,000 revolutionary blood tests for NHS lung and breast cancer patients | EQS-News: SYNLAB
/ Key word(s): Miscellaneous
Synnovis milestone: 2,000 revolutionary blood tests for NHS lung and breast cancer patients
10.08.2026 / 09:00 CET/CEST
The... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| HCA HEALTHCARE | 347,00 | -0,37 % | William R. Keating acquires Capital One and HCA Inc. notes via Focus Partners IRA | ||
| LANTHEUS | 86,90 | -0,34 % | Lantheus Holdings, Inc.: Lantheus Announces FDA Approval of TAUKLARIFY (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer's Disease | BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians... ► Artikel lesen | |
| CAREDX | 40,200 | 0,00 % | Top Biotech Gainers: CareDx Soars On Medicare Policy, ATAI Acquired, Abbott Laboratories Lifts Outlook, APLM On Watch | NORTH CHICAGO (dpa-AFX) - Today's top gainers in the biotech space include CareDx, which rallied after Medicare finalized its Local Coverage Determination process for molecular testing of solid... ► Artikel lesen | |
| ENVISTA | 23,400 | 0,00 % | Can NVST Sustain Its 2026 Guidance Boost as Margins Keep Expanding? | ||
| GT BIOPHARMA | 0,275 | -3,40 % | GT Biopharma, Inc.: GT Biopharma Reports Second Quarter 2026 Financial Results | Phase 1 trial evaluating GTB-3650 TriKE- remains ongoing, with an update anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE- in multiple solid tumor types known to express B7-H3... ► Artikel lesen | |
| SYNEOS HEALTH | - | - | Causaly and Syneos Health Partner to Raise the Scientific Intensity of Clinical Research | Collaboration embeds evidence-grounded agentic AI into scientific workflows across Syneos Health, accelerating research while strengthening scientific rigor, consistency, and sponsor valueLONDON... ► Artikel lesen | |
| CARMAT | 0,049 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.03.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.03.2026.ISIN NameCA4013392051 GUARDIAN... ► Artikel lesen | |
| CHEMOMETEC | 62,00 | -0,32 % | ChemoMetec A/S: ChemoMetec enters collaboration agreement with Roche Diagnostics | ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties' solutions in... ► Artikel lesen |